Imprimis Pharma (IMMY) Reports Q3 Loss of $0.28, Miss on Revenues

Imprimis Pharma (NASDAQ: IMMY) reported Q3 EPS of ($0.28), versus $0.00 reported last year. Revenue for the quarter came in at $6.5 million versus the consensus estimate of $6.86 million.

Third Quarter 2017 and Recent Financial Highlights:

• Gross ophthalmology-related revenue of $4.9 million, up over 60% year-over-year
• 503B revenue up to $2.6M for the quarter, up 14% quarter-over-quarter
• Average 503B order exceeded $1,300 for the quarter
• 503B gross margin exceeded internal target of 60%
• Revenue of $6.5 million, up 34% year-over-year
• Adjusted EBITDA loss of $1.6 million, a 45% improvement year-over-year

For earnings history and earnings-related data on Imprimis Pharma (IMMY) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Zeo Energy Corp (ZEO) Misses Q2 EPS by 7c
• Edible Garden AG (EDBL) Reports Q2 Loss of $18.79